Evaluation of hepatocellular carcinoma models for preclinical studies

Drug Discovery Today: Disease Models

Volumn 2, Issue 1, 2005, Pages 41-49

  Kramer, M Gabriela ^a   Hernandez Alcoceba, Ruben ^a   Qian, Cheng ^a   Prieto, Jesus ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; HEPATITIS B SURFACE ANTIGEN; MYC PROTEIN; NUCLEOSIDE ANALOG; PROTEIN BCL 2; PROTEIN P53; TRANSCRIPTION FACTOR E2F1; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE KINASE RECEPTOR; WNT PROTEIN;

ADENOVIRUS; CANCER MODEL; CLINICAL STUDY; COMPUTER MODEL; EXPERIMENTAL DESIGN; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 21644453593     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2005.05.009     Document Type: Review

References (98)

1. K. Okuda Hepatocellular carcinoma J. Hepatol. 32 2000 225-237
2. F.X. Bosch et al. Primary liver cancer: Worldwide incidence and trends Gastroenterology 127 2004 S5-S16
3. M.A. Buendia Genetics of hepatocellular carcinoma Semin. Cancer Biol. 10 2000 185-200
4. S.S. Thorgeirsson and J.W. Grisham Molecular pathogenesis of human hepatocellular carcinoma Nat. Genet. 31 2002 339-346
5. L.V. Rubinstein et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines J. Natl. Cancer Inst. 82 1990 1113-1118
6. T.O. Kirby et al. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity Clin. Cancer Res. 10 2004 8697-8703
7. R. Bilbao et al. A blood-tumor barrier limits gene transfer to experimental liver cancer: The effect of vasoactive compounds Gene Ther. 7 2000 1824-1832
8. R.C. Liang et al. Proteome database of hepatocellular carcinoma J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 771 2002 303-328
9. J.S. Lee et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling Hepatology 40 2004 667-676
10. M.F. Yuen and C.L. Lai Serological markers of liver cancer Best Pract. Res. Clin. Gastroenterol. 19 2005 91-99
11. Z.Y. Tang et al. A decade's studies on metastasis of hepatocellular carcinoma J. Cancer Res. Clin. Oncol. 130 2004 187-196
12. Z.Y. Li et al. Xenograft models for liver metastasis: Relationship between tumor morphology and adenovirus vector transduction Mol. Ther. 9 2004 650-657
13. Y. Shimosato et al. Transplantation of human tumors in nude mice J. Natl. Cancer Inst. 56 1976 1251-1260
14. J. Marx Medicine. Building better mouse models for studying cancer Science 299 2003 1972-1975
15. C. Wilmanns et al. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil Int. J. Cancer 52 1992 98-104
16. F.X. Sun et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues Int. J. Cancer 66 1996 239-243
17. B. Rashidi et al. An orthotopic mouse model of remetastasis of human colon cancer liver metastasis Clin. Cancer Res. 6 2000 2556-2561
18. R.M. Hoffman Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: A bridge to the clinic Invest. New Drugs 17 1999 343-359
19. M. Barajas et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12 Hepatology 33 2001 52-61
20. E. Chun and K.Y. Lee Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells Biochem. Biophys. Res. Commun. 315 2004 771-779
21. Y. Wang et al. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray Cancer 95 2002 2346-2352
22. S.Y. Paik et al. Expression of transforming growth factor-beta1 and transforming growth factor-beta receptors in hepatocellular carcinoma and dysplastic nodules Mod. Pathol. 16 2003 86-96
23. A. Musch et al. Altered expression of TGF-beta receptors in hepatocellular carcinoma - effects of a constitutively active TGF-beta type I receptor mutant Digestion 71 2005 78-91
24. E. Santoni-Rugiu et al. Acceleration of c-myc-induced hepatocarcinogenesis by co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption Am. J. Pathol. 154 1999 1693-1700
25. A. de La Coste et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas Proc. Natl. Acad. Sci. USA 95 1998 8847-8851
26. A. Cadoret et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin Cancer Res. 61 2001 3245-3249
27. M.L. Martinez-Chantar et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A FASEB J. 16 2002 1292-1294
28. S. Sell Mouse models to study the interaction of risk factors for human liver cancer Cancer Res. 63 2003 7553-7562
29. H. Okabe et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progression Cancer Res. 61 2001 2129-2137
30. J.S. Pagano et al. Infectious agents and cancer: Criteria for a causal relation Semin. Cancer Biol. 14 2004 453-471
31. L.M. Sargent et al. Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver Am. J. Pathol. 154 1999 1047-1055
32. Y. Wu et al. Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors Oncogene 21 2002 1518-1526
33. O. Terradillos et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice Oncogene 14 1997 395-404
34. Y. Wang et al. Different expression of hepatitis B surface antigen between hepatocellular carcinoma and its surrounding liver tissue, studied using a tissue microarray J. Pathol. 197 2002 610-616
35. K. Moriya et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice Nat. Med. 4 1998 1065-1067
36. J.S. Lee et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer Nat. Genet. 36 2004 1306-1311
37. D.F. Calvisi et al. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice Gastroenterology 126 2004 1374-1386
38. A. Luch Nature and nurture - lessons from chemical carcinogenesis Nat. Rev. Cancer 5 2005 113-125
39. E. Farber and D.S. Sarma Hepatocarcinogenesis: A dynamic cellular perspective Lab. Invest. 56 1987 4-22
40. A. Sanchez et al. STAT-3 activity in chemically-induced hepatocellular carcinoma Eur. J. Cancer. 39 2003 2093-2098
41. N. Horiguchi et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine Oncogene 21 2002 1791-1799
42. Y.S. Ho and J.K. Lin N-nitroso-2-acetylaminofluorene: A direct-acting carcinogen inducing hepatocellular carcinoma in Sprague-Dawley rats Jpn. J. Cancer Res. 85 1994 794-800
43. C. Qian et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma Hum. Gene Ther. 8 1997 349-358
44. R.Q. Yan et al. Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1 J. Cancer Res. Clin. Oncol. 122 1996 289-295
45. F. Gyorkey et al. Experimental carcinoma of liver in macaque monkeys exposed to diethylnitrosamine and hepatitis B virus J. Natl. Cancer Inst. 59 1977 1451-1467
46. D.H. Jeong et al. Hepatic cirrhosis occurring in a young woodchuck (Marmota monax) due to vertical transmission of woodchuck hepatitis virus (WHV) J. Vet. Sci. 4 2003 199-201
47. B.C. Tennant et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection Gastroenterology 127 2004 S283-S293
48. J.R. Jacob et al. Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors Hepatology 39 2004 1008-1016
49. R. Bilbao et al. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: The woodchuck animal model Cancer Gene Ther. 7 2000 657-662
50. T. Zhao et al. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo Cancer Res. 63 2003 3073-3078
51. M. Takahashi et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor Mol. Ther. 5 2002 627-634
52. F. Mawatari et al. Retrovirus-mediated gene therapy for hepatocellular carcinoma: Selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhancer directly linked to its promoter Cancer Gene Ther. 5 1998 301-306
53. Y. Li A et al. hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin Cancer Res. 61 2001 6428-6436
54. S.C. Heffelfinger et al. SK HEP-1: A human cell line of endothelial origin In Vitro Cell. Dev. Biol. 28A 1992 136-142
55. S. Kaneko et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression Cancer Res. 55 1995 5283-5287
56. E. Chun et al. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model Int. J. Cancer 114 2005 124-130
57. J.Z. Huang et al. Effects of p16 gene on biological behaviours in hepatocellular carcinoma cells World J. Gastroenterol. 9 2003 84-88
58. C.Q. Ling et al. Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma Ann. Oncol. 16 2005 109-115
59. Z.Y. Tang et al. Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential World J. Gastroenterol. 7 2001 597-601
60. J. Tian et al. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis Br. J. Cancer 81 1999 814-821
61. Y. Li et al. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics J. Cancer Res. Clin. Oncol. 130 2004 460-468
62. X.W. Wang et al. Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice World J. Gastroenterol. 7 2001 345-351
63. W. Jiao et al. Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitro and in vivo Br. J. Cancer. 86 2002 98-101
64. C.F. Grimm et al. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice Gastroenterology 119 2000 1104-1112
65. T. Tatsumi et al. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma Cancer Res. 61 2001 7563-7567
66. Y.I. Yamashita et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model Cancer Res. 61 2001 1005-1012
67. V. Schmitz et al. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma Hepatology 34 2001 72-81
68. J. Ryall et al. Regulation and expression of carbamyl phosphate synthetase I mRNA in developing rat liver and Morris hepatoma 5123D J. Biol. Chem. 259 1984 9172-9176
69. G. Calviello et al. Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: Effects on proliferation and apoptosis Int. J. Cancer. 75 1998 699-705
70. G.F. Barnard et al. Regulation of lipoprotein receptors on rat hepatomas in vivo Biochim. Biophys. Acta 879 1986 301-312
71. M.H. Pourgholami et al. Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol Cancer Lett. 207 2004 37-47
72. R. Rowley et al. In vivo tumour-cell proliferation after adriamycin treatment Br. J. Cancer 45 1982 429-437
73. N. Carbo et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats Br. J. Cancer 83 2000 526-531
74. S.B. Lin et al. In vitro and in vivo suppression of growth of rat liver epithelial tumor cells by antisense oligonucleotide against protein kinase C-alpha J. Hepatol. 33 2000 601-608
75. T.T. Wissniowski et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits Cancer Res. 63 2003 6496-6500
76. M. Mirowski et al. Expression of 65-kDa oncofetal protein in experimental hepatoma after anticancer therapy Neoplasma 44 1997 85-89
77. M. Unoura et al. Establishment of a cell line from a woodchuck hepatocellular carcinoma Hepatology 5 1985 1106-1111
78. H. Lee et al. Establishment and characterization of a diethylnitrosamine-initiated woodchuck hepatocyte cell line Hepatology 7 1987 937-940
79. J. Etiemble et al. Liver-specific expression and high oncogenic efficiency of a c-myc transgene activated by woodchuck hepatitis virus insertion Oncogene 9 1994 727-737
80. N. Cartier et al. Diet-dependent carcinogenesis of pancreatic islets and liver in transgenic mice expressing oncogenes under the control of the L-type pyruvate kinase gene promoter Oncogene 7 1992 1413-1422
81. A. de La Coste et al. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice Cancer Res. 59 1999 5017-5022
82. E. Santoni-Rugiu et al. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model Proc. Natl. Acad. Sci. USA 93 1996 9577-9582
83. E.A. Conner et al. E2F1 blocks and c-Myc accelerates hepatic ploidy in transgenic mouse models Biochem. Biophys. Res. Commun. 302 2003 114-120
84. C. Jhappan et al. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas Cell 61 1990 1137-1146
85. E. Gilbert et al. In vivo effects of activated H-ras oncogene expressed in the liver and in urogenital tissues Int. J. Cancer. 73 1997 749-756
86. R.R. Tonjes et al. Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice Oncogene 10 1995 765-768
87. J. Borlak et al. Epidermal growth factor-induced hepatocellular carcinoma: Gene expression profiles in precursor lesions, early stage and solitary tumours Oncogene 24 2005 1809-1819
88. E.A. Conner et al. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis Oncogene 19 2000 5054-5062
89. L. Amicone et al. Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: Importance of TGF-beta signalling in the control of liver homeostasis and transformation Oncogene 21 2002 1335-1345
90. V.M. Factor et al. Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice Cancer Res. 57 1997 2089-2095
91. K. Nicholes et al. A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice Am. J. Pathol. 160 2002 2295-2307
92. F.V. Chisari et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice Cell 59 1989 1145-1156
93. H.A. Dunsford et al. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice Cancer Res. 50 1990 3400-3407
94. A.R. Sepulveda et al. Development of a transgenic mouse system for the analysis of stages in liver carcinogenesis using tissue-specific expression of SV40 large T-antigen controlled by regulatory elements of the human alpha-1-antitrypsin gene Cancer Res. 49 1989 6108-6117
95. E.P. Sandgren et al. Oncogene-induced liver neoplasia in transgenic mice Oncogene 4 1989 715-724
96. L.M. Sargent et al. Specific chromosomal changes in albumin simian virus 40 T antigen transgenic rat liver neoplasms Cancer Res. 57 1997 3451-3456
97. Y.P. Dragan et al. Alterations in specific gene expression and focal neoplastic growth during spontaneous hepatocarcinogenesis in albumin-SV40 T antigen transgenic rats Mol. Carcinog. 40 2004 150-159
98. M. Suggitt and M.C. Bibby 50 years of preclinical anticancer drug screening: Empirical to target-driven approaches Clin. Cancer. Res. 11 2005 971-981